DOCSLIB.ORG

New Products Issue 2-2015

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
New Products Issue 2-2015 u e n mb u e s r s i ∙ ∙ 2 2 0 1 5 new products! Chiron AS Stiklestadvn. 1 N-7041 Trondheim Norway Phone No.: +47 73 87 44 90 Fax No.: +47 73 87 44 99 E-mail: [email protected] Website: www.chiron.no Org. No.: NO 967 607 657 MVA NEW PRODUCTS Issue No. 2, 2015 Toxicology Chiron Cat. No. Name CAS No. Antidepressants 10841.17 Chlorpromazine-d6 oxalate (N,N-dimethyl-d6) N/A 10853.19 Imipramine hydrochloride 113-52-0 10732.13 Moclobemide 71320-77-9 10862.19 Trazodone hydrochloride 25332-39-2 Antipsychotics 10808.18 Clozapine-n-oxide 34233-69-7 10807.17 Norclozapine 6104-71-8 10856.20 Prochloroperazine maleate 84-02-6 10835.21 Quetiapine hemifumarate 111974-72-2 Anti-Infectives 10845.22 Amikacin 37517-28-5 10824.16 Cefotaxime sodium salt 64485-93-4 10847.22 Chlortetracycline hydrochloride 64-72-2 10826.17 Ciprofloxacin hydrochloride 86483-48-9 10829.19 Cloxacillin sodium 642-78-4 10827.17 Meropenem trihydrate 119478-56-7 10828.16 Penicillin G sodium salt 113-98-4 10823.10 Piperacillin sodium salt 59703-84-3 10857.20 Quinine hemi-sulfate 6119-70-6 10825.10 Tazobactam 89786-04-9 10858.22 Tetracycline hydrochloride 64-75-5 10860.18 Tobramycin 32986-56-4 Cannabinoids (Synthetic) 10751.24 APICA N-(4-hydroxypentyl) metabolite N/A 10725.23 APINACA N-(4-hydroxypentyl) metabolite N/A 10834.16 B-22 3-carboxyindole metabolite 858515-71-6 10796.13 5-Fluoropentylindole N/A 10832.15 Methyl (1-cyclohexylmethyl)indole-3 carboxylate 858515-82-9 10795.17 Methyl 1-(5-fluoropentyl)-1H-indole-3-carboxylate N/A 10833.15 Methyl 1-pentylindole-3-caroboxylate 1338925-20-4 10836.14 PB-22 3-carboxyindole metabolite 727421-73-0 10727.14 5F-PB-22 3-carboxyindole metabolite 1432794-98-3 10788.21 UR-144 N-(5-hydroxypentyl) metabolite 895155-95-0 10789.16 UR-144 pentyl-COOH metabolite 1451369-33-7 Chiron AS Stiklestadvn. 1 N-7041 Trondheim Norway Phone No.: +47 73 87 44 90 Fax No.: +47 73 87 44 99 E-mail: [email protected] Website: www.chiron.no Org. No.: NO 967 607 657 MVA Chiron Cat. No. Name CAS No. Cardiac Drugs 10844.18 Acebutolol hydrochloride 34381-68-5 10846.25 Amiodarone hydrochloride 19774-82-4 10849.16 D-Propranolol hydrochloride 13071-11-9 10850.16 L-Propranolol hydrochloride 4199-10-4 10855.17 Nifedipine 21829-25-4 10859.18 Timolol maleate 26921-17-5 Cocaines 10816.16 Benzoylecgonine-d3 115732-68-8 10815.17 Cocaine-13C6-d3 hydrochloride N/A Opioids 10822.22 Dihydrocodeine hydrogen tartrate 5965-13-9 10721.16 Noroxymorphone hydrochloride 52446-24-9 Steroids 10798.19 trans-Androsterone 481-29-8 10812.19 6-Bromoandrostenedione 38632-00-7 10811.20 Halodrol N/A Other Pharmaceuticals 10731.21 Biperiden (Mixture of diasteromers) 514-65-8 10793.21 Biperiden hydrochloride (Mixture of diasteromers) 1235-82-1 10729.20 (+)-Chlorpheniramine maleate 2438-32-6 10730.6 Clomethiazole 533-45-9 10848.18 Cyclizine 82-92-8 10813.4 GABA 56-12-2 10743.9 5-IAI hydrochloride N/A 10854.14 Lignocaine hydrochloride 73-78-9 10746.6 Piracetam 7491-74-9 10747.6 Piracetam-d8 1329799-64-5 10864.10 Serotonin-13C2, 15N hydrochloride 153-98-0 (unlabelled) 10863.14 Stiripentol 49763-96-4 10861.12 Tolbutamide 64-77-7 Contrast Media 10768.18 Diatrizoic acid meglumine salt 131-49-7 10749.20 Iodipamide 606-17-7 10769.19 Iohexol 66108-95-0 10805.17 Iopamidol 60208-45-9 (racemic) 10754.11 Iopanoic acid 96-83-3 10748.18 Iotalamic acid meglumine salt 13087-53-1 10750.24 Ioxaglic acid 59017-64-0 Chiron AS Stiklestadvn. 1 N-7041 Trondheim Norway Phone No.: +47 73 87 44 90 Fax No.: +47 73 87 44 99 E-mail: [email protected] Website: www.chiron.no Org. No.: NO 967 607 657 MVA Environmental & Food Safety Chiron Cat. No. Name CAS No. Alkylbenzenes 01082.23 n-Heptadecylbenzene 14752-75-1 01081.22 n-Hexadecylbenzene 1459-09-2 01076.15 n-Nonylbenzene 1081-77-2 01083.24 n-Octadecylbenzene 4445-07-2 Pesticides 10819.15 Propoxycarbazone-sodium 181274-15-7 10820.14 Prosulfocarb 52888-80-9 Phenols 10772.21 Bisphenol A Bis(2-hydroxypropyl) ether 116-37-0 10791.14 4-n-Octylphenol-d4 1246815-03-1 Phthalates 10852.14 Bis(2-ethoxyethyl) adipate 109-44-4 10839.26 Bis(2-ethylhexyl) sebacate 122-62-3 Miscellaneous Compounds 10733.18 1-Octadecene, analytical grade, 99.5% 112-88-9 10817.7 Benzoic acid sodium salt 532-32-1 10809.30 Chaetocin 28097-03-2 10806.6 Dimethyl fumarate-2,3-d2 23057-98-9 10728.4 Methional 13C3 (1,2,3-13C3) N/A 10818.6 Potassium sorbate 24634-61-5 For ordering and information about prices and delivery in your country, please contact your local distributor: Chiron AS Stiklestadvn. 1 N-7041 Trondheim Norway Phone No.: +47 73 87 44 90 Fax No.: +47 73 87 44 99 E-mail: [email protected] Website: www.chiron.no Org. No.: NO 967 607 657 MVA.
Load more

Recommended publications
  • Biosimilar Branded Iodinated Contrast Agents Related to the Largest Number of Reports to the Who-Pharmacovigilance System Over the First 40 Years of the Programme
    Pharmacologyonline 2: 929-962 (2011) Newsletter Bradu and Rossini BIOSIMILAR BRANDED IODINATED CONTRAST AGENTS RELATED TO THE LARGEST NUMBER OF REPORTS TO THE WHO-PHARMACOVIGILANCE SYSTEM OVER THE FIRST 40 YEARS OF THE PROGRAMME. FIFTH WHO-ITA/ITA-OMS 2010-2011 CONTRIBUTION Dan Bradu and Luigi Rossini* Servizio Nazionale collaborativo WHO-ITA/ITA-OMS, Universita’ Politecnica delle Marche e Progetto di Farmacotossicovigilanza pre-, post-marketing, Azienda Ospedaliera Universitaria Ospedali Riuniti di Ancona, Regione Marche, Italia Summary Analysis of the side-events, and suspicious or confirmed adverse drug reactions (SADRs), accounting for a total of 67,232 reports, based on the model and on a Matlab program (as described in the fourth contribution of our current series) showed broadly inhomogeneous profiles of all of the 10 products categorized as “biosimilar” that have been the object of the largest number of reports in the first 40 years of the WHO Pharmacovigilance Programme. The analysis highlighted striking differences both when they were subdivided into system-organ class disorders (SOCDs) or studied together, and when they were analyzed in terms of five pairs of biosimilars and their respective, agreed, generic reference products. These conclusions add to the data, already reported by the authors, of the preclinical experiments and the pre-marketing conventional standardized clinical trials regulations. Key words: WHO International Drug Monitoring, Pharmacovigilance Programme. Correlation objective autoclassificative and confirmatory clustering comparisons between couples of ATC- 929 Pharmacologyonline 2: 929-962 (2011) Newsletter Bradu and Rossini V08A-A 8 Amidotrizoate, Iotalamate, Ioxitalamate and Metrizoate, and ATC-V08A-B 2 Ioxaglate “biosimilars”. ----------------------------------------------------------------------------------------------------------------------- -* Corresponding author, retired October 31, 2008.
    [Show full text]
  • Iopanoic Acid/Iotalamic Acid 1485
    Iopanoic Acid/Iotalamic Acid 1485 Iopromide (BAN, USAN, rINN) Profile USP 31 (Iothalamic Acid). A white, odourless, powder. Slightly Iopydol is an iodinated radiographic contrast medium (p.1474) soluble in water and in alcohol; soluble in solutions of alkali hy- Iopromida; Iopromidum; Jopromid; Jopromidi; ZK-35760. N,N′- that has been used with iopydone for bronchography. droxides. Store at a temperature of 25°, excursions permitted be- Bis(2,3-dihydroxypropyl)-2,4,6-tri-iodo-5-(2-methoxyacetami- tween 15° and 30°. do)-N-methylisophthalamide. Йопромид Iopydone (BAN, USAN, rINN) Meglumine Iotalamate (BANM, rINNM) C H I N O = 791.1. 18 24 3 3 8 Iopidona; Iopydonum. 3,5-Di-iodo-4-pyridone. CAS — 73334-07-3. Iotalamate de Méglumine; Iotalamato de meglumina; Iothalamate ATC — V08AB05. Йопидон Meglumine; Meglumine Iothalamate; Meglumini Iotalamas. The N-methylglucamine salt of iotalamic acid. ATC Vet — QV08AB05. C5H3I2NO = 346.9. CAS — 5579-93-1. Меглумина Йоталамат C11H9I3N2O4,C7H17NO5 = 809.1. OH H CAS — 13087-53-1. N ATC — V08AA04. HO ATC Vet — QV08AA04. HN II I O Description. Meglumine iotalamate contains about 47.1% of I. O O Pharmacopoeias. US includes only as various injections. I CH3 Description. Iopydone contains about 73.2% of I. H3C N O Profile Sodium Iotalamate (BANM, rINNM) Iopydone is an iodinated radiographic contrast medium (p.1474) I HN that has been used with iopydol for bronchography. Iotalamate de Sodium; Iotalamato de sodico; Iotalamato de so- HO O dio; Iothalamate Sodium; Natrii Iotalamas; Sodium Iothalamate. OH Натрий Йоталамат Iosarcol (pINN) C H I N NaO = 635.9. Description. Iopromide contains about 48.1% of I.
    [Show full text]
  • Verg(H)Ulde Pillen – Casestudie Lumc, Leiden Verg(H)Ulde Pillen
    STICHTING TOEGEPAST ONDERZOEK WATERBEHEER VERG(H)ULDE PILLEN – CASESTUDIE LUMC, LEIDEN VERG(H)ULDE PILLEN [email protected] WWW.stowa.nl TEL 030 232 11 99 FAX 030 232 17 66 CASESTUDIE LUMC, LEIDEN Arthur van Schendelstraat 816 POSTBUS 8090 35 03 RB UTRECHT 2009 RAPPORT W02 2009 W02 VERG(H)ULDE PILLEN CASESTUDIE LUMC TE LEIDEN 2009 RAPPORT W02 ISBN 978.90.5773.428.1 [email protected] WWW.stowa.nl Publicaties van de STOWA kunt u bestellen op www.stowa.nl. TEL 030 232 11 99 FAX 030 231 79 80 Deze publicatie is ook digitaal beschikbaar. Arthur van Schendelstraat 816 POSTBUS 8090 3503 RB UTRECHT STOWA 2009-W02 VERG(H)ULDE PILLEN – DEEL B LUMC – LEIDEN COLOFON Utrecht, 2009 Uitgave STOWA 2009 Arthur van Schendelstraat 816 Postbus 8090 3503 RB Utrecht Tel 030 2321199 Fax: 030 2321766 e-mail: [email protected] http://www.stowa.nl Auteur(s) dr. S.A.E. Kools dr. ir. M.W. Kuiper dr. ir. J.H. Roorda ir. J.G.M. Derksen De begeleidingscommissie was opgebouwd uit vertegenwoordigers vanuit de waterwereld en vertegenwoordigers vanuit de ziekenhuizen. Deze bestond uit de volgende personen: Harm Baten (Hoogheemraadschap van Rijnland) Pieter de Bekker (Hoogheemraadschap de Stichtse Rijnlanden) Marja Bogaards (Reinier de Graaf Gasthuis) Bart Hellings (Ministerie van VROM) Desiree Hoefnagel (Ministerie van VWS) Bert Palsma (STOWA) Ellen Parma (Milieuplatform Zorg; de helft van alle Nederlandse ziekenhuizen is hierbij aangesloten ) Percival Stubbs (Nederlandse Vereniging van Ziekenhuizen; alle Nederlandse ziekenhuizen zijn hierbij aangesloten) Ferdinand Kiestra (Waterschap Aa en Maas) Erica Mosch (Waterschap Hunze en Aa’s) Gerard Rijs (Waterdienst – Rijkswaterstaat) Esther Willems (MPZ) Peter van Zundert (Ministerie Verkeer en Waterstaat) Deze publicatie is ook digitaal beschikbaar Prepress/druk Van de Garde | Jémé STOWA Rapportnummer 2009-W02 STOWA 2009-W02 VERG(H)ULDE PILLEN – DEEL B LUMC – LEIDEN SAMENVATTING In Nederland worden 12.000 verschillende geneesmiddelen met ongeveer 850 verschillende actieve stoffen gebruikt, waarbij het geneesmiddelengebruik per inwoner jaarlijks stijgt.
    [Show full text]
  • Lääkealan Turvallisuus- Ja Kehittämiskeskuksen Päätös
    Lääkealan turvallisuus- ja kehittämiskeskuksen päätös N:o xxxx lääkeluettelosta Annettu Helsingissä xx päivänä maaliskuuta 2016 ————— Lääkealan turvallisuus- ja kehittämiskeskus on 10 päivänä huhtikuuta 1987 annetun lääke- lain (395/1987) 83 §:n nojalla päättänyt vahvistaa seuraavan lääkeluettelon: 1 § Lääkeaineet ovat valmisteessa suolamuodossa Luettelon tarkoitus teknisen käsiteltävyyden vuoksi. Lääkeaine ja sen suolamuoto ovat biologisesti samanarvoisia. Tämä päätös sisältää luettelon Suomessa lääk- Liitteen 1 A aineet ovat lääkeaineanalogeja ja keellisessä käytössä olevista aineista ja rohdoksis- prohormoneja. Kaikki liitteen 1 A aineet rinnaste- ta. Lääkeluettelo laaditaan ottaen huomioon lää- taan aina vaikutuksen perusteella ainoastaan lää- kelain 3 ja 5 §:n säännökset. kemääräyksellä toimitettaviin lääkkeisiin. Lääkkeellä tarkoitetaan valmistetta tai ainetta, jonka tarkoituksena on sisäisesti tai ulkoisesti 2 § käytettynä parantaa, lievittää tai ehkäistä sairautta Lääkkeitä ovat tai sen oireita ihmisessä tai eläimessä. Lääkkeeksi 1) tämän päätöksen liitteessä 1 luetellut aineet, katsotaan myös sisäisesti tai ulkoisesti käytettävä niiden suolat ja esterit; aine tai aineiden yhdistelmä, jota voidaan käyttää 2) rikoslain 44 luvun 16 §:n 1 momentissa tar- ihmisen tai eläimen elintoimintojen palauttami- koitetuista dopingaineista annetussa valtioneuvos- seksi, korjaamiseksi tai muuttamiseksi farmako- ton asetuksessa kulloinkin luetellut dopingaineet; logisen, immunologisen tai metabolisen vaikutuk- ja sen avulla taikka terveydentilan
    [Show full text]
  • Alphabetical Listing of ATC Drugs & Codes
    Alphabetical Listing of ATC drugs & codes. Introduction This file is an alphabetical listing of ATC codes as supplied to us in November 1999. It is supplied free as a service to those who care about good medicine use by mSupply support. To get an overview of the ATC system, use the “ATC categories.pdf” document also alvailable from www.msupply.org.nz Thanks to the WHO collaborating centre for Drug Statistics & Methodology, Norway, for supplying the raw data. I have intentionally supplied these files as PDFs so that they are not quite so easily manipulated and redistributed. I am told there is no copyright on the files, but it still seems polite to ask before using other people’s work, so please contact <[email protected]> for permission before asking us for text files. mSupply support also distributes mSupply software for inventory control, which has an inbuilt system for reporting on medicine usage using the ATC system You can download a full working version from www.msupply.org.nz Craig Drown, mSupply Support <[email protected]> April 2000 A (2-benzhydryloxyethyl)diethyl-methylammonium iodide A03AB16 0.3 g O 2-(4-chlorphenoxy)-ethanol D01AE06 4-dimethylaminophenol V03AB27 Abciximab B01AC13 25 mg P Absorbable gelatin sponge B02BC01 Acadesine C01EB13 Acamprosate V03AA03 2 g O Acarbose A10BF01 0.3 g O Acebutolol C07AB04 0.4 g O,P Acebutolol and thiazides C07BB04 Aceclidine S01EB08 Aceclidine, combinations S01EB58 Aceclofenac M01AB16 0.2 g O Acefylline piperazine R03DA09 Acemetacin M01AB11 Acenocoumarol B01AA07 5 mg O Acepromazine N05AA04
    [Show full text]
  • Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DIX to the HTSUS—Continued
    20558 Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DEPARMENT OF THE TREASURY Services, U.S. Customs Service, 1301 TABLE 1.ÐPHARMACEUTICAL APPEN- Constitution Avenue NW, Washington, DIX TO THE HTSUSÐContinued Customs Service D.C. 20229 at (202) 927±1060. CAS No. Pharmaceutical [T.D. 95±33] Dated: April 14, 1995. 52±78±8 ..................... NORETHANDROLONE. A. W. Tennant, 52±86±8 ..................... HALOPERIDOL. Pharmaceutical Tables 1 and 3 of the Director, Office of Laboratories and Scientific 52±88±0 ..................... ATROPINE METHONITRATE. HTSUS 52±90±4 ..................... CYSTEINE. Services. 53±03±2 ..................... PREDNISONE. 53±06±5 ..................... CORTISONE. AGENCY: Customs Service, Department TABLE 1.ÐPHARMACEUTICAL 53±10±1 ..................... HYDROXYDIONE SODIUM SUCCI- of the Treasury. NATE. APPENDIX TO THE HTSUS 53±16±7 ..................... ESTRONE. ACTION: Listing of the products found in 53±18±9 ..................... BIETASERPINE. Table 1 and Table 3 of the CAS No. Pharmaceutical 53±19±0 ..................... MITOTANE. 53±31±6 ..................... MEDIBAZINE. Pharmaceutical Appendix to the N/A ............................. ACTAGARDIN. 53±33±8 ..................... PARAMETHASONE. Harmonized Tariff Schedule of the N/A ............................. ARDACIN. 53±34±9 ..................... FLUPREDNISOLONE. N/A ............................. BICIROMAB. 53±39±4 ..................... OXANDROLONE. United States of America in Chemical N/A ............................. CELUCLORAL. 53±43±0
    [Show full text]
  • Hotspotanalyse Emissie Medicijnresten in Flevoland
    Hotspotanalyse emissie medicijnresten in Flevoland Definitief In opdracht van: Waterschap Zuiderzeeland Grontmij Nederland B.V. De Bilt, 11 maart 2015 GM-0153094, revisie D2 Verantwoording Titel : Hotspotanalyse emissie medicijnresten in Flevoland Subtitel : Projectnummer : 340355 Referentienummer : GM-0153094 Revisie : D2 Datum : 11 maart 2015 Auteur(s) : dr. A.A. Vergouwen; dr. M.J.M. Vissers; ir. J.B.M. van Acker E-mail adres : [email protected]; [email protected] Gecontroleerd door : dr. A.A. Vergouwen Paraaf gecontroleerd : Goedgekeurd door : dr.ir. A.J. Oomens Paraaf goedgekeurd : Contact : Grontmij Nederland B.V. De Holle Bilt 22 3732 HM De Bilt Postbus 203 3730 AE De Bilt T +31 88 811 66 00 F +31 30 220 02 94 www.grontmij.nl GM-0153094, revisie D2 Pagina 2 van 52 Inhoudsopgave 1 Inleiding .................................................................................................................... 5 1.1 Inleiding .................................................................................................................... 5 1.2 Doel .......................................................................................................................... 5 1.3 Uitgangspunten en randvoorwaarden ........................................................................ 5 1.4 Leeswijzer ................................................................................................................. 5 2 Algemene informatie ................................................................................................
    [Show full text]
  • Stembook 2018.Pdf
    The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances FORMER DOCUMENT NUMBER: WHO/PHARM S/NOM 15 WHO/EMP/RHT/TSN/2018.1 © World Health Organization 2018 Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-nc-sa/3.0/igo). Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition”. Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization. Suggested citation. The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances. Geneva: World Health Organization; 2018 (WHO/EMP/RHT/TSN/2018.1). Licence: CC BY-NC-SA 3.0 IGO. Cataloguing-in-Publication (CIP) data.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2016/0348103 A1 WHEELER Et Al
    US 201603481 03A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2016/0348103 A1 WHEELER et al. (43) Pub. Date: Dec. 1, 2016 (54) OLIGONUCLEOTIDES AND METHODS FOR Related U.S. Application Data TREATMENT OF CARDIOMYOPATHY USING RNA INTERFERENCE (60) 27,Provisional 2014. application No. 61/931,690, filed on Jan. (71) Applicant: THE BOARD OF TRUSTEE OF Publication Classification THE LELAND STANFORD JUNOR UNIVERSITY, Palo Alto, CA (US) (51) Int. Cl. (72) Inventors: Matthew WHEELER, Sunnyvale, CA CI2N IS/II3 (2006.01) US); Euan A. ASHLEY. Menlo Park (52) U.S. Cl. CA(US), (US); Eua Katheia AA M. , Menlo Park, CPC ......... CI2N 15/113 (2013.01); C12N 2310/14 ZALETA-RIVERA, Stanford, CA (US) (2013.01) (73) Assignee: The Board of Trustees of the Leland (57) ABSTRACT Stanford Junior University, Stanford, Compositions and methods for treating cardiomyopathy CA (US) using RNA interference are disclosed. In particular, embodi ments of the invention relate to the use of oligonucleotides (21) Appl. No.: 15/114,063 for treatment of cardiomyopathy, including Small interfering RNAs (siRNAs) and short hairpin RNAs (shRNAs) that (22) PCT Filed: Jan. 26, 2015 silence expression of disease-causing mutant alleles, such as the myosin MYL2 allele encoding human regulatory light (86). PCT No.: PCT/US2O15/O12966 chain (hRLC)-N47K and the MYH7 allele encoding human S 371 (c)(1), myosin heavy chain (hMHC)-R403O while retaining (2) Date: Jul. 25, 2016 expression of the corresponding wild-type allele. Patent Application Publication Dec. 1, 2016 Sheet 1 of 38 US 2016/0348103 A1 Patent Application Publication Dec.
    [Show full text]
  • Ep 2263709 A1
    (19) & (11) EP 2 263 709 A1 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: (51) Int Cl.: 22.12.2010 Bulletin 2010/51 A61L 31/16 (2006.01) A61L 27/54 (2006.01) A61L 27/34 (2006.01) A61L 29/08 (2006.01) (2006.01) (2006.01) (21) Application number: 10182123.9 A61L 29/16 A61L 31/10 (22) Date of filing: 10.03.2003 (84) Designated Contracting States: (72) Inventors: AT BE BG CH CY CZ DE DK EE ES FI FR GB GR • Cromack, Keith, R. HU IE IT LI LU MC NL PT RO SE SI SK TR Gurnee,, IL 60031 (US) • Toner, John, L. (30) Priority: 06.09.2002 US 235572 Libertyville, IL 60048 (US) 10.09.2002 PCT/US02/28798 10.09.2002 PCT/US02/28776 (74) Representative: Modiano, Micaela Nadia et al Modiano & Partners (62) Document number(s) of the earlier application(s) in Thierschstrasse 11 accordance with Art. 76 EPC: 80538 München (DE) 03714060.5 / 1 536 850 Remarks: (71) Applicant: Abbott Laboratories This application was filed on 29-09-2010 as a Abbott Park, IL 60064-6008 (US) divisional application to the application mentioned under INID code 62. (54) Medical device having hydration inhibitor (57) Medical devices comprising an interventional anti-thrombotic agents, cytotoxic drugs, agents that in- component for delivering multiple beneficial agents in hibit cytokine or chemokine binding, cell de-differentia- which a hydration inhibitor controls release of at least tion inhibitors, anti- lipacdemic agents, matrix metallopro- one beneficial agent from the device. The hydration in- teinase inhibitors, cytostatic drugs, or combinations of hibitor is relatively less hydrophilic than the beneficial these drugs, radiopaque markers, beta-carotene, toco- agent and preferably is a drug.
    [Show full text]
  • Electrochemical Oxidation of Iodinated X-Ray Contrast Media by Boron-Doped Diamond Electrodes
    Desalination and Water Treatment (2017) 1–5 www.deswater.com doi: 10.5004/dwt.2017.20535 Electrochemical oxidation of iodinated X-ray contrast media by boron-doped diamond electrodes A.-L. Schneidera, S. Tislera, H. Schella, T. Matthéeb, B. Behrendt-Frydab, A. Tiehma,* aDepartment of Environmental Biotechnology, DVGW-Technologiezentrum Wasser, Karlsruher Strasse 84, 76139 Karlsruhe, Germany, Tel. +49 721 9678 137; emails: [email protected] (A. Tiehm), [email protected] (A.-L. Schneider), [email protected] (H. Schell) bCONDIAS GmbH, Fraunhofer Strasse 1b, 25524 Itzehoe, Germany, Tel. +49 4821 80 40 87 0; emails: [email protected] (T. Matthée), [email protected] (B. Behrendt-Fryda) Received 29 November 2016; Accepted 20 January 2017 abstract Iodinated X-ray contrast media (IXCM) represent widespread water pollutants due to their poor elimination by common wastewater treatment techniques such as aerobic and anaerobic biodegradation. In this study, we demonstrate the removal of six IXCM (iotalamic acid, iopami- dol, iohexol, iopromide, iomeprol and diatrizoate) by electrochemical treatment with boron-doped diamond electrodes. Experiments were performed with model solutions and field water samples. Electrochemical treatment of IXCM in synthetic solution resulted in complete deiodination and gen- eration of the oxidation product iodate. We observed a dissolved organic carbon (DOC) decrease of 30%–80% in IXCM solutions, indicating partial mineralisation. Electrochemical IXCM degradation followed pseudo-first-order kinetics. In experiments with surface water and effluent from a wastewater treatment plant, successful degradation of IXCM was achieved despite the high DOC background. These results demonstrate that electrochemical treatment is a promising method for IXCM removal.
    [Show full text]
  • Table 4: Protective Action Criteria (PAC) Rev. 29 Based on Applicable
    Table 4: Protective Action Criteria (PAC) Rev. 29a based on applicable 60-minute AEGLs, ERPGs, or TEELs. The chemicals are 3 listed in alphabetical order and the values are presented in mg/m . June 2018 Table 4 is an alphabetical list of the chemical substances and their corresponding PAC values in mass per unit volume (mg/m3). The conversion of ppm to mg/m3 was carried out assuming normal temperature and pressure, 25°C and 760 mm Hg. The columns presented in Table 4 provide the following information: Heading Definition No. The ordered numbering of the chemicals as they appear in this alphabetical listing Chemical Name The name of the chemical substance submitted to the PAC development team CASRN The Chemical Abstracts Service Registry Number1 for this chemical PAC-1 Based on the applicable AEGL-1, ERPG-1, or TEEL-1 value PAC-2 Based on the applicable AEGL-2, ERPG-2, or TEEL-2 value PAC-3 Based on the applicable AEGL-3, ERPG-3, or TEEL-3 value Chemicals for which AEGLs are available have their chemical name, CASRN, and AEGL values displayed in a bolded and larger font. Chemicals for which ERPGs are available, but not AEGLs, have their chemical name, CASRN, and ERPG values displayed in a bolded font. Chemicals for which TEELs are available, but no AEGLs or ERPGs, have their chemical name, CASRN, and values displayed using a regular font. Additional information on PAC values and TEEL values and links to other sources of information is provided on the Subcommittee on Consequence Assessment and Protective Actions (SCAPA) webpage at http://orise.orau.gov/emi/scapa/default.htm.
    [Show full text]